PARSIPPANY, N.J., April 30, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today reported net income for the first quarter 2012 increased 87 percent to $208.8 million or $1.64 per diluted share on a non-GAAP basis, compared to $111.9 million or $0.89 per diluted share in the first quarter 2011.  On a GAAP basis, net revenue increased 74 percent to $1.5 billion, compared to $876.5 million in the first quarter 2011. GAAP earnings per diluted share for the first quarter 2012 were $0.43, compared to $0.36 in the prior year period.

For the first quarter 2012, adjusted EBITDA increased 70 percent to $367.2 million, compared to $215.9 million for the first quarter 2011.   Cash and marketable securities were $182.2 million as of March 31, 2012. Refer to the attached reconciliation tables for adjustments to GAAP earnings.

"Substantial double-digit revenue growth across our three businesses – Global Generics, Global Brands and Anda distribution – drove an 84 percent increase in non-GAAP earnings per share, and a $151 million increase in Adjusted EBITDA" said Paul Bisaro, President and CEO. 

"In our Global Generics business, we launched more than 60 new products and filed 28 applications globally. We also expanded our presence in Australia and Southeast Asia with the acquisition of Ascent Pharmahealth Limited. In our Global Brands business, we initiated the phase III study in the U.S. for Esmya, launched a brand product portfolio in Canada and continued our biologics development efforts on rFSH and the Amgen portfolio of products," Bisaro continued.

"Watson maintained its record of solid performance in 2012, performance that enables us to execute on our business strategies including increasing our Global Generics business presence with the acquisition of Actavis Group. We will continue to look for strategic opportunities to propel Global Brands and biologics growth and will remain focused on the expansion of our Anda business into specialty distribution," concluded Bisaro. 

Business Segment Results

Global Generics net revenue for the first quarter 2012 increased 86 percent to $1.1 billion as a result of new product launches and higher international net revenue.  New products include the generic versions of Concerta® and Lipitor® launched in May 2011 and November 2011, respectively and the launch in the first quarter of a generic version of Lovenox®. First quarter 2012 international net revenue was $171.7 million, up 58 percent from the first quarter 2011 as a result of the acquisition of Specifar Pharmaceuticals in May 2011 and Ascent Pharmahealth Limited in January 2012 and new launches in key markets.

Global Generics R&D investment for the first quarter 2012 increased 3 percent to $56.1 million and Global Generics selling and marketing expenses for the first quarter 2012 increased $16.9 million, primarily due to the addition of Specifar and Ascent.

Adjusted Global Generics gross margin decreased from 51.8 percent in the first quarter 2011 to 45.1 percent in the first quarter 2012, due to sales of the authorized generic versions of Lipitor^® and Concerta^® at lower margins.  

Global Brands net revenue increased 13 percent to $109.6 million in the first quarter 2012. The increase in revenue was primarily the result of increased sales of Rapaflo^® and Crinone^® and the addition of new products including Generess^® Fe and Androderm^® 2mg and 4mg in the U.S. and Rapaflo^® and Gelnique^® in Canada.

Global Brands R&D investment increased 63 percent to $32.4 million in the first quarter 2012 compared to the first quarter 2011. The increase was a result of higher contractual milestones for the initiation of the Phase III U.S. study for Esmya and for rFSH and investments related to biologics development.   Global Brands selling and marketing expenses increased 31 percent to $47.7 million in the first quarter 2012 as a result of higher field force support costs related to expansions in the U.S. and Canada that occurred in the second half of 2011.

Global Brands segment gross margin for the first quarter 2012 was 76.5 percent, compared to 81.6 percent for first quarter 2011 as a result of a favorable product mix in the prior year period.

Distribution segment net revenue for the first quarter 2012 increased 66 percent to $298.6 million compared to $179.5 million in the first quarter 2011. The increase was related to higher third-party product launches, higher base business sales and logistical services provided to certain chain customers in the current year period. Distribution revenue consists only of sales of third-party products and excludes sales of Watson's brand and generic products.

Selling and marketing expenses increased $4.5 million to $22.9 million, primarily due to higher freight costs expenses associated with relocating our Groveport, Ohio distribution operations to our Olive Branch, Mississippi facility. Distribution segment adjusted gross margin decreased to 11.5 percent in the first quarter 2012 due to logistic services provided to certain chain customers.

Other Operating Expenses
Consolidated general and administrative expenses were $164.4 million in the first quarter 2012, an increase of 107 percent from the first quarter 2011. The increase was primarily as a result of charges related to certain litigation matters and the additions of Specifar and Ascent.  Amortization expense for the first quarter 2012 was $131.9 million, compared to $56.6 million in first quarter 2011. The increase was primarily the result of the amortization of atorvastatin product rights acquired in the Arrow acquisition and product rights acquired in the Specifar and Ascent acquisitions.

2012 Financial Outlook
Watson's estimates are based on actual results for the first quarter 2012 and management's current belief about prescription trends, pricing levels, inventory levels and the anticipated timing of future product launches and events. Watson's forecast for 2012 excludes any effect from the pending acquisition of Actavis Group which is expected to close in the fourth quarter of 2012.

-- Watson estimates total net revenue for 2012 will be approximately $5.5 billion.

• Total Global Generics segment revenue of between $3.9 and $4.1 billion.
• Total Global Brands segment revenue of between $500 and $525 million.
• Total Anda Distribution segment revenue of between $950 million and $1 billion.
• Adjusted non-GAAP earnings for 2012 is expected to be between $5.55 and $5.80 per diluted share.
• Adjusted EBITDA for 2012 is expected to be between $1.310 and $1.375 billion.

Webcast and Conference Call Details
Watson will host a conference call and webcast today at 8:30 a.m. Eastern Daylight Time to discuss first quarter 2012 results, the outlook for 2012 and recent corporate developments.  The dial-in number to access the call is (877) 251-7980, or from international locations, (706) 643-1573.  The Conference ID is 73123257.

A taped replay of the conference call will also be available beginning approximately two hours after the call's conclusion and will remain available through 12:00 midnight Eastern Time on May 14, 2012.  The replay may be accessed by dialing (855) 859-2056 and entering the same Conference ID above. From international locations, the replay may be accessed by dialing (404) 537-3406.  To access the webcast, go to Watson's Investor Relations Web site at http://ir.watson.com.  

About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc., is a leading integrated global pharmaceutical company. The Company is engaged in the development, manufacturing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement
Statements contained in this press release that refer to Watson's estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. For instance, any statements in this press release concerning prospects related to Watson's strategic initiatives, product introductions and anticipated financial performance are forward-looking statements. It is important to note that Watson's goals and expectations are not predictions of actual performance. Watson's performance, at times, will differ from its goals and expectations. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the inherent uncertainty associated with financial projections; successful integration of the Ascent acquisition and the ability to recognize the anticipated synergies and benefits of the Ascent acquisition; the difficulty of predicting the timing and outcome of pending litigation and risks that an adverse outcome in such litigation could render Watson liable for substantial damages; the impact of competitive products and pricing; risks related to fluctuations in foreign currency exchange rates; periodic dependence on a small number of products for a material source of net revenue or income; variability of trade buying patterns; changes in generally accepted accounting principles; risks that the carrying values of assets may be negatively impacted by future events and circumstances; the timing and success of product launches; the difficulty of predicting the timing or outcome of product development efforts and regulatory agency approvals or actions if any; market acceptance of and continued demand for Watson's products; costs and efforts to defend or enforce intellectual property rights; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with governmental regulations applicable to Watson's facilities, products and/or businesses; changes in the laws and regulations, including Medicare, Medicaid, and similar laws in foreign countries affecting, among other things, pricing and reimbursement of pharmaceutical products and the settlement of patent litigation; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on form 10-K for the year ended December 31, 2011. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

All trademarks are the property of their respective owners.  

The following table presents Watson's results of operations for the three months ended
March 31, 2012 and 2011:

The following table presents Watson's Condensed Consolidated Balance Sheet at March 31, 2012 and at December 31, 2011.

The following table presents Watson's Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2012 and 2011.

The following table presents a reconciliation of reported net income and diluted earnings per share to non-GAAP net income for the three months ended March 31, 2012 and 2011:

The following table presents a reconciliation of reported net income for the three months ended March 31, 2012 and 2011 to adjusted EBITDA:

The following table presents a reconciliation of forecasted net income for the twelve months ending December 31, 2012 to non-GAAP net income and non-GAAP earnings per diluted share:

The reconciliation table is based in part on management's estimate of non-GAAP net income for the year ending December 31, 2012.  Watson expects certain known GAAP charges for 2012, as presented in the schedule above.  Other GAAP charges that may be excluded from non-GAAP net income are possible, but their amounts are dependent on numerous factors that we currently cannot ascertain with sufficient certainty or are presently unknown.  These GAAP charges are dependent upon future events and valuations that have not yet been performed.  Watson's forecast for 2012 excludes any impact from the pending acquisition of Actavis Group which is expected to close in the fourth quarter of 2012.

The following table presents a reconciliation of forecasted net income for the twelve months ending December 31, 2012 to adjusted EBITDA:

The reconciliation table is based in part on management's estimate of adjusted EBITDA for the year ending December 31, 2012.  Watson expects certain known GAAP charges for 2012, as presented in the schedule above.  Other GAAP charges that may be excluded from estimated EBITDA are possible, but their amounts are dependent on numerous factors that we currently cannot ascertain with sufficient certainty or are presently unknown.  These GAAP charges are dependent upon future events and valuations that have not yet been performed.  Watson's forecast for 2012 excludes any impact from the pending acquisition of Actavis Group which is expected to close in the fourth quarter of 2012.

(Logo:  http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )

SOURCE Watson Pharmaceuticals, Inc.